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a systematic monitoring, as in pharmaceutical care services, seeking to promote 
safety of pharmacotherapy.
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OBJECTIVES: To study the risk of nephrotoxicity and the cost of treatment of colis-
tin. METHODS: Patients admitted in ICU with resistant bacterial infections and on 
colistin for at least seven days were included in the study. They were observed for 
any change in Glomerular filtration rate and the risk of nephrotoxicity according 
to the RIFLE criteria after the colistin therapy. The GFR values before the initiation 
of treatment with colistin were compared with that after the end of regimen. The 
pre and post treatment GFR values were compared using non-parametric Wilcoxon 
Signed Ranks test. RESULTS: A total of 30 patients on colistin were observed dur-
ing the study. The mean age of the patients was 45.47±16.45. The average APACHE 
II score was 15.87±5.82. There was no significant difference between the GFR of 
patients before and after treatment with colistin (p= 0.130). The average hospitali-
zation cost was 255245.41±138099.29 and the average cost of colistin therapy was 
31638.10±12625.90. CONCLUSIONS: This study showed that the nephrotoxic effect 
of colistin is not significant. There is a need to conduct more studies with a higher 
sample size to assess the risk of colistin-induced nephrotoxicity. The incidences 
of nephrotoxicity in the patients studied can be attributed to various other factors 
such as age, comorbidities etc. The cost of colistin therapy was substantial being 
more than one-tenth of the total hospitalization cost.
PIN3
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OBJECTIVES: Invasive candidiasis is an important cause of complication and mor-
tality of inpatient. Anidulafungin as others echinocandins are drugs that have 
shown clinical relevance in the treatment of invasive candidiasis. This research 
sought to evaluate the effectiveness and safety of anidulafungin in comparison 
to fluconazole, amphotericin B deoxycholate, amphotericin B liposomal, caspo-
fungin and micafungin for the treatment of invasive candidiasis among non-neu-
tropenicpatients above 16 years. METHODS: We performed a systematic review 
in which were included randomized clinical trials (RCT) evaluating the different 
drugs to treatment of invasive candidiasis in non-neutropenic patients. It involved 
in MEDLINE, EMBASE, Cochrane, DARE and LILACS. The quality of evidence and risk 
of bias of clinical trials were assessed with GRADE tool and Cochrane methodol-
ogy respectively. We performed a meta-analysis and Bayesian mixed treatment 
comparison (MTC) to compare the effectiveness and safety of the different con-
sidered treatment. The outcomes of effectiveness and safetywere global response 
rate, mortality and occurrence serious event adverse (SEA). RESULTS: We included 
11 RCT and clinical evidence provided was of moderate quality according to the 
GRADE system. For global response rate, the MTC displayed that anidulafungin 
was more effective than fluconazole (OR 2.07 IC95% 1.20- 2.59). In comparison with 
others drugs, anidulafungin presented similar effectiveness (non-significant sta-
tistically differences). In mortality, it presented less proportion of events (29,5% 
IC95% 18,8-42,0) than other interventions, but it was not statistically different of 
them. Anidulafungin showed better safety profile than amphotericin B deoxycholate 
regarding to occurrence of SEA (OR 0.15 IC95% 0.02-0.97). However, there were not 
significantly statistical differences with amphotericin B liposomal, caspofungin and 
fluconazole. CONCLUSIONS: The MTC found that anidulafungin is more effective 
than fluconazole and exhibited similar effectiveness than others interventions. With 
respect to safety profile, anidulafungin was superior to amphotericin B deoxycolate 
and similar to the others.
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BACKGROUND: A landmark in the prevention of serious respiratory syncytial 
virus (RSV) infection was established with the release of palivizumab, a recom-
binant, humanized, genetically-engineered monoclonal antibody. Palivizumab 
has been deemed safe in clinical trials without major, serious adverse events 
(SAEs). OBJECTIVES: The primary objective of this study is to evaluate the safety 
and tolerability of palivizumab for RSV infection prophylaxis in high-risk chil-
dren. METHODS: High-risk children prophylaxed against RSV infection were 
recruited into a prospective, observational, Canadian RSV Evaluation Study of 
Palivizumab (CARESS) registry with active SAE monitoring from 2008 to 2013. SAE 
reports were systematically collected and assessed for severity and relationship to 
palivizumab. Data were analyzed by using Chi-square or Fisher Exact Tests to exam-
ine group differences in proportions. RESULTS: 13,025 infants were enrolled and 
received 57,392 injections: premature infants ≤ 35 weeks gestational age (n= 8224; 
63.1%), children aged < 2 years with chronic lung disease (n= 978; 7.5%), hemody-
namically significant congenital heart disease (n= 1442; 11.1%) and pre-existing 
medical disorders (n= 2381; 18.3%). 915 patients were hospitalized for a respiratory 
OBJECTIVES: To provide real-world evaluations of newer direct-acting antivirals 
(DAAs) in CHC patients from large US payer perspectives. METHODS: Medical and 
pharmacy claims linked to lab data from the Humana Database were analyzed for 
Medicare Advantage or commercially-insured adults with ≥ 2 CHC claims (ICD-9 
070.44; 070.54) who received therapy containing SMV and/or SOF through June 2014; 
those with HIV were excluded. Patients were grouped based on most common regi-
mens in the data: SMV/SOF, SMV/SOF/ribavirin (RBV), SOF/RBV, or SOF/interferon 
(IFN)/RBV; < 3% received other regimens. Baseline (BL) demographics and clinical 
characteristics (e.g., claims-based cirrhosis or end stage liver disease [ESLD], FIB-4 
scores) were described and post-treatment time measured. Methods to control for 
treatment selection bias were not performed, and comparative analyses were not 
conducted. RESULTS: There were 715 CHC patients who received therapy with SMV/
SOF (n= 184), SMV/SOF/RBV (n= 37), SOF/RBV (n= 269) or SOF/IFN/RBV (n= 225); mean 
age was between 60-62 years; 58%, 68%, 62% and 70% were male; most (85%, 78%, 
81% and 80%) had Medicare. For SMV/SOF, SMV/SOF/RBV, SOF/RBV, and SOF/IFN/
RBV groups, BL cirrhosis was present in 27%, 27%, 17%, and 24% of patients and 
ESLD in 48%, 38%, 27%, and 12% of patients, respectively. Slightly over half in each 
cohort had calculable FIB-4 scores, of which, 56%, 54%, 34% and 35%, respectively, 
had scores > 3.25. Among those with genotype data, 100% (78/78) SMV/SOF, 94.7% 
(18/19) SMV/SOF/RBV, 24.4% (29/119) SOF/RBV and 95.8% (92/96) SOF/IFN/RBV were 
genotype 1. Using prior claims history, 10%, 19%, 12% and 17% of respective cohorts 
were treatment-experienced. Less than half of each cohort had post-treatment data 
≥ 1 week. CONCLUSIONS: This analysis of CHC patients predominantly insured 
through Medicare found that the majority of those who received SMV/SOF +/- RBV 
had either cirrhosis or ESLD claims prior to therapy and, based on lab data, over 
half had FIB-4 scores > 3.25.
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OBJECTIVES: New Hepatitis C (HCV) antivirals have been shown to be highly effective 
with minimal side effects. These medications are costly and have raised significant 
concern from insurers, policymakers, advocacy groups, and patients about afford-
ability. However, little is known about the impact of new HCV antiviral expenditures. 
The objective of this study was to describe HCV antiviral expenditures by agent, 
year, and healthcare sector in the US. METHODS: HCV antiviral (interferon/ribavirin, 
telaprevir, simeprevir, sofosbuvir, boceprevir) expenditures from 10/1/2008-9/30/2014 
were obtained from the IMS Health© National Sales Perspectives database. This 
dataset represents a near-census view of US medication purchases. Expenditures 
were totaled by drug, sector, and year (defined as 10/1-9/30). Growth was calculated 
as the % increase compared to the previous year/period. RESULTS: A total of $12.2 
billion in HCV drugs were purchased from 10/2008-9/2014, 70.2% in 2014. HCV anti-
viral expenditures increased 10,880% over the six-years. Expenditures decreased by 
$7.8 million in 10/2012-9/2013 as compared to 10/2011-9/2012 (-41% growth). While 
the majority of expenditures in 10/2008-9/2010 were for interferons, this shifted to 
telaprevir in 10/2010-9/2013 and sofosbuvir in 10/2013-9/2014. Sofosbuvir was 55% of 
HCV drug expenditures over the study period and 78% in 10/2013-9/2014. By sector, 
mail order (59%) and retail (27%) pharmacies were associated with the majority of 
expenditures. CONCLUSIONS: New HCV antivirals are driving the increased expen-
ditures for this class. Decreased expenditures in 10/2012-9/2013 may have been 
secondary to delaying HCV treatment until new therapies received FDA-approval 
(“warehousing”). With continued drug development and approval of HCV therapies, 
expenditures are expected to continue to increase, barring actions by payers that 
may impede this trend. Medication policies guiding HCV treatment should focus on 
safety and efficacy while balancing the long-term costs of HCV. With the majority of 
expenditures originating from outpatient pharmacies, pharmacists are an essential 
partner to ensure appropriate use.
INfectION – clINIcAl OutcOmes studIes
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OBJECTIVES: Adverse Drug Reactions (ADR) are one of the main problems related 
to antiretroviral (ARV) therapy and often result in decreased adherence and thera-
peutic failure. This study aimed to analyze the ADR that manifested during the 
Pharmacotherapeutic Monitoring (AFT) of HIV+ patients. METHODS: This was 
a longitudinal study carried out in accordance to the Dader Method of pharma-
ceutical care, which monitored 100 HIV+ patients in a center of medical spe-
cialties in Fortaleza-CE-Brazil, from November/2008 to January/2012. Data were 
collected from individual pharmacotherapeutic follow-up forms. The ADRs were 
classified according to causality as “definite, probable, possible, conditional and 
non-related” and gravity as “mild, moderate, severe and fatal”, using the World 
Health Organization (2002) method. RESULTS: Of the reported RAM (n = 267), the 
two most affected systems by ADR were the gastrointestinal tract (n = 117, ex. 
diarrhea, nausea and vomiting) and the nervous system (n= 101, ex. dizziness, 
nightmares and delusions). As for the classes of ARVs that were involved with ADR, 
the Nucleoside Reverse-Transcriptase Inhibitors (n = 113), followed by inhibitors 
non-Nucleoside Reverse-Transcriptase inhibitors (n= 73) observations and protease 
inhibitors (n = 49), were the most frequent. With regard to causality, 80.9% of RAM 
(n = 216) were classified as possible and 19.1% as probable (n = 51). As for gravity, 
85% (n = 176) were mild and 15% (n = 40) moderate. CONCLUSIONS: Data ratified 
that ARVs are triggers of ADR and its use need to be continually followed through 
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older than those without (37.5 vs. 34.5, p = 0.0017). The prevalence rate among all 
patients were 7.6% for diabetes, 13.3% for hypertension, 23.4% for hyperlipidemia, 
as compared to 3.4%, 8.5% and 6.8% in patients without HAART. There were sta-
tistically significant differences for diabetes (p = 0.0294) and hyperlipidemia (p < 
0.0001). The difference for hypertension is boradline statistically significant (p = 
0.0601). The mean expenditure per patient per year of dyslipidemia drugs, hypo-
glycemic drug, antihypertensive drug, and sedative hypnotic drug were not statisti-
cally significant. CONCLUSIONS: Per previous literature reviews, the prevalence of 
diabetes, hypertension, hyperlipidemia for HIV-infected patients with HAART was 
confirmed and increasing year by year using the real world data in Taiwan. Good 
control of metabolic co-morbidities to reduce the risk of morbidity and mortality 
is highly recommended.
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OBJECTIVES: E. coli is the most frequently encountered pathogen in clinical set up 
causing devastating infections irrespective of age and gender resulting in signifi-
cant morbidity and mortality. E. coli isolates have been found resistant to variety 
of antibiotics commonly used in empirical therapy at hospitals and clinics. CTX-M, 
TEM and SHV type extended spectrum beta-lactamases are mainly responsible 
for this resistance. The aim of this study was to investigate the prevalence of CTX-
M, TEM and SHV beta-lactamases in clinical isolates of E. coli and to assess the 
resulted economic burden on the poor population. METHODS: E. coliisolates were 
collected from a tertiary care hospital between 2012 and 2013, and tested against 
several classes of antibiotics on Kirby- Bauer disk diffusion methods to check their 
multidrug resistance phenotype. Presence and identification of CTX-M, SHV and 
TEM beta-lactamases were confirmed on PCR. RESULTS: Overall resistance pat-
tern to the tested antibiotics was amoxicillin(80%), cefazolin(74%), cefotaxime(63%), 
ceftazidime(58%), gentamycin(58%), ciprofloxacin(89%), levofloxacin(51%), chloram-
phenicol(38%), erythromycin(83%), amoxicillin/clavulanic acid(82%) and trimetho-
prim/sulfamethoxazole(91%). The prevalence of different beta-lactamase types in E. 
coliisolates was CTX-M(72 %), TEM(67%) and SHV(53%). CONCLUSIONS: CTX-M, TEM 
and SHV beta-lactamases are responsible for such overwhelming resistance in these 
isolates. These enzymes are present on mobile genetic elements such as plasmids 
which are readily exchanged between diverse bacterial communities and leading 
this alarming resistance to epidemic level. More than 50% of population live below 
the poverty line in Pakistan and cannot afford or have excess to expensive treat-
ments, such resistance is challenging the very health care system of the country. 
Both rate of infections and resistance to antimicrobials is on the rise and is sped 
up by the unregulated sub-standard health practice in Pakistan. The current health 
and economic losses are incalculable but the more devastating consequences to the 
humanity and economy are not too far from reality.
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OBJECTIVES: H1N1 influenza infection associated with higher morbidity and mor-
tality because of associated severe complications like acute respiratory distress 
syndrome (ARDS) and multiple organs dysfunction syndrome. We conducted a ret-
rospective study to evaluate the clinical characteristics, different complication and 
management strategies adopted to treat H1N1 patients in a tertiary care centre. To 
study the clinical features, complication, different risk factors affecting the outcome 
along with different management strategies used in the patients with confirmed 
H1N1influenza infection. METHODS: The medical records of 141 patients were ana-
lyzed retrospectively who were admitted to KMC Hospital, Manipal, from June 2012 
through May 2014. RESULTS: Among the study population 51.1% were female with 
mean age of 32.54 years. Among 55.3% patients admitted without any significant 
medical history and 44.7% patients had major problems like diabetes mellitus, res-
piratory tract infections and bronchial asthma. Fever with headache was observed 
in 92.9% followed by cough (78.7%) and breathlessness (54.6%). According to severity 
of disease 53.2% patients were put on mechanical ventilation. All the patients were 
started with oseltemivir for influenza management. The co-infections were treated 
by beta-lactams (60.28%) and macrolides (41.11%). Diuretics were given in 32.46%, 
anti-anxiety in 31.90% patients and antipyretics, bronchodilators and corticoster-
oids as supportive care in all patients. Mean of hospitalization period was 8.5 days. 
During the hospitalization the patients developed different complications like res-
piratory tract infections (31.20%), ARDS (17.7%) and sepsis (14.4%). The mortality rate 
of the study population was found to be 29.1 %. CONCLUSIONS: We observed that 
outcome was associated with low oxygen saturation during admission, metabolic 
acidosis, abnormal chest x-rays, use of diuretics, corticosteroids and anti-anxiety 
drugs. We also found that the complications like ARDS, sepsis and respiratory tract 
infections also influence the mortality rate.
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OBJECTIVES: This study assessed length of stay (LOS), inpatient costs and mortal-
ity among hospitalized patients with cSSSI treated with ceftaroline compared with 
illness (RIH rate: 7.03%) of which 196 tested RSV-positive (RSVH rate: 1.76%). All RIHs 
were not or probably not related to palivizumab. 62 single or multiple SAEs were 
documented in 52 infants. Fourteen events in 6 patients out of 62 SAEs were hyper-
sensitivity reactions (moderate: 11; mild: 3). These were deemed possibly (n= 10) or 
probably (n= 4) related to palivizumab (rate: 0.00028 events per patient-month). The 
remaining 48 SAEs in 46 patients were categorized as not related (n= 39), probably 
not related (n= 5), and unclassifiable (n= 4). CONCLUSIONS: Using an active surveil-
lance system, a very small proportion of infants in the CARESS registry experienced 
SAEs that had a clear relationship with palivizumab and these events appear to 
be idiosyncratic. In routine practice, palivizumab appears to be a safe and well-
tolerated antibody for RSV infection prophylaxis in high-risk children.
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OBJECTIVES: While infectious disease societies recommend weight-based loading 
doses of 25-30 mg/kg in critically ill patients, published meta-analyses describe 
increased vancomycin related nephrotoxicity at these doses. Our objective was to 
assess incidence of nephrotoxicity with vancomycin in emergency department (ED) 
sepsis patients when compliant with these recommendations. METHODS: This was 
a retrospective cohort study performed in three EDs. An electronic health record 
(EHR)-based clinical decision support tool provided guidance at the point of order for 
IV vancomycin compliant with recommendations. Inclusion criteria: age ≥ 18 years, 
IV vancomycin order, and hospital admission. Exclusion criteria: no documented 
weight, hemodialysis-dependent, or < 2 creatinine (Cr) values. The primary outcome 
was incidence of nephrotoxicity within 5 days defined as at least 2 serial Cr higher 
than the initial measurement by at least 0.5 mg/dL or 50% increase. The secondary 
outcome was acute kidney injury (AKI) within 5 days, defined as any single increase 
in Cr by 0.5mg/dL or 50%. Analyses compared the incidence of nephrotoxicity and 
AKI between patients who received high dose (> 20 mg/kg) versus low dose (≤ 20 mg/
kg). Parametric data were compared using the t-test and categorical data with chi-
squared tests. RESULTS: An EHR-based query identified 2131 consecutive patients 
prescribed IV vancomycin over 6 months. Of these, 1330 patients met study criteria 
for the primary outcome and 1631 patients met criteria for the secondary outcome. 
Nephrotoxicity occurred in 8% of patients. High dose vancomcyin was associated 
with a lower rate of nephrotoxicity (6% vs 11%, p< 0.05) and a lower rate of AKI (8% 
vs 13%, p< 0.05). CONCLUSIONS: Initial dosing of vancomycin > 20 mg/kg according 
to guidelines was associated with a decreased rate of nephrotoxicity compared with 
low doses. Future analyses should distinguish between the occurrence of nephro-
toxicity due to disease progression in severe sepsis versus vancomycin exposure.
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OBJECTIVES: The aim of this study was to reassess the safety profile of fluoroqui-
nolones using the database of adverse drug reactions (ADR) Spontaneous report 
system and the purchases data of fluoroquinolones. METHODS: All ADRs reported 
related to fluoroquinolones were retrieved from Center for Drug Monitoring and 
Evaluation (CDME) of Hebei. Reports were classified by System Organ Classes with 
MedDRAÂ®. Consumption data (numbers of defined daily dose [DDDs]) were used 
as denominators.Reporting rate and types of ADRs between different drugs were 
checked with Pearson’s chi-squared test, and a p-value of < 0.05 was considered 
statistically significant. RESULTS: Fluoroquinolones common ADRs related to skin 
and subcutaneous tissue, gastrointestinal, general disorders and administration site 
conditions. No delayed ADR or death caused by ADR was reported. Ofloxacin, levo-
floxacin and ciprofloxacin showed the lowest reporting rate adjusted by consump-
tion data. CONCLUSIONS: These data suggest that different fluoroquinolones were 
characterized by different rates and types of ADRs. In current application of fluoro-
quinolones, clinicians did not pay sufficient attention to delayed-ADRs and ADRs 
resulting in glucose metabolism disorder, which might lead to more safety problems.
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OBJECTIVES: Highly active antiretroviral therapy (HAART) was available for HIV-
infected patients in Taiwan since 1997. HAART can effectively reduce mortality 
and morbidity, but it may also increase the risk and related drug costs of metabolic 
co-morbidities for HIV-infected patients. The aim of this research was to investi-
gate the prevalence and treatment costs of metabolic co-morbidities such as dia-
betes, hypertension, and hyperlipidemia between HAART treated and not treated 
patients. METHODS: We conducted a population-based study using 1M sampling 
version of the National Health Insurance Research Database (NHIRD) from Taiwan 
between 2010 and 2012. We extracted HIV-infected patients from both outpatient 
and inpatient with primary or secondary diagnosis of HIV (ICD codes 042-044). 
Treatments such as HAART and other related information were extracted. The 
prevalence and related drug costs of metabolic co-morbidities was estimated and 
comparison were made using SAS version 9.3. RESULTS: In the sampling database, 
there were 488 and 235 HIV-infected patients with and without HAART treatments. 
They were mainly male (94.6% vs. 90.2%, p = 0.0255), HAART treated patients were 
